Zobrazeno 1 - 10
of 3 593
pro vyhledávání: '"First-line therapy"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract This systematic review and network meta-analysis evaluates first-line treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and brain metastases. We analyzed 24 randomized controlled trials (RCTs) involving 2,682
Externí odkaz:
https://doaj.org/article/8ebe442c00564a6bbb358712a3a844c2
Autor:
Anna Tanaka, Shuhei Teranishi, Yukihito Kajita, Tomofumi Hirose, Ayami Kaneko, Yu Sairenji, Hidetoshi Kawashima, Kentaro Yumoto, Toshinori Tsukahara, Kenji Miura, Nobuaki Kobayashi, Masaki Yamamoto, Ryuichi Nishihira, Makoto Kudo, Naoki Miyazawa, Masanori Nishikawa, Takeshi Kaneko
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionTotal baseline tumor size (BTS) is a prognostic factor for programmed death 1 and programmed death-ligand 1 (PD-L1) inhibitor treatments. However, the prognostic value of total BTS for patients with small-cell lung cancer (SCLC) who recei
Externí odkaz:
https://doaj.org/article/99db2f11197c43fb830593424fcc72e2
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveThis study aimed to investigate the efficacy, long-term prognosis and safety of combining chemotherapy with regorafenib and immune checkpoint inhibitors as first-line treatment for patients with advanced biliary tract carcinoma (BTC).Methods
Externí odkaz:
https://doaj.org/article/388225d5fa314e8a83123fe283fac02c
Autor:
Kaakour D, Nagasaka M
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 49-54 (2024)
Dalia Kaakour,1 Misako Nagasaka1,2 1Department of Internal Medicine, Division of Hematology and Oncology, University of California Irvine School of Medicine Chao Family Cancer Center, Orange, CA, USA; 2Department of Medicine, St. Marianna University
Externí odkaz:
https://doaj.org/article/3cc5d6293b9e47ee904fd1f43aec2c28
Autor:
Bertrand Mennecier, Jonathan Khalifa, Renaud Descourt, Laurent Greillier, Charles Naltet, Lionel Falchero
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background We designed this study based on both a physician practice survey and real-world patient data to: (1) evaluate clinical management practices in extensive-stage small cell lung cancer (ES-SCLC) among medical centers located across F
Externí odkaz:
https://doaj.org/article/3557946ac2fc4245980868df6de93f27
Autor:
Wenjing Liu, Lulin Yu, Yuqian Feng, Siyu Huang, Yuxin Hua, Mingying Peng, Shanming Ruan, Kai Zhang
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 7, Pp n/a-n/a (2024)
ABSTRACT Background In this network meta‐analysis (NMA), the efficiency and safety of PD‐1 inhibitors + chemotherapy and PD‐L1 inhibitors + chemotherapy were compared in the first‐line therapy of patients with extensive‐stage small cell lun
Externí odkaz:
https://doaj.org/article/772dba9e0953458a8adfb35376114e7e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundRecently, a sum of trials of programmed cell death-1 (PD-1) inhibitors combined with chemotherapy have shown excellent efficacy compared to chemotherapy alone in patients with previously untreated, advanced esophageal squamous cell carcinom
Externí odkaz:
https://doaj.org/article/850822955b224e7dbafb236b943d88d3
Autor:
Mahn R, Glüer OA, Sadeghlar F, Möhring C, Zhou T, Anhalt T, Monin MB, Kania A, Glowka TR, Feldmann G, Brossart P, Kalff JC, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 81-94 (2024)
Robert Mahn,1,* Oscar André Glüer,1,* Farsaneh Sadeghlar,1 Christian Möhring,1 Taotao Zhou,1 Thomas Anhalt,1 Malte Benedikt Monin,1 Alexander Kania,2 Tim R Glowka,2 Georg Feldmann,3 Peter Brossart,3 Joerg C Kalff,2 Ingo GH Schmidt-Wolf,4 C
Externí odkaz:
https://doaj.org/article/7b0e6b47d2314e87ba683eca85fb6ff5
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10311-10324 (2023)
Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with metastatic castration-resistant prostate cancer (mCRPC). We systemati
Externí odkaz:
https://doaj.org/article/4e06a29a46b84d40bd74b6c214cad917
Autor:
Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
Publikováno v:
Surgery Open Science, Vol 16, Iss , Pp 171-183 (2023)
Background: The purpose of this study was to compare the efficacy and safety of utidelone plus capecitabine for advanced first-line versus second-line or above therapy in metastatic breast cancer patients who had previously received anthracycline and
Externí odkaz:
https://doaj.org/article/d1be5d327d924e8c993092066e383afe